Can the administration of testosterone to men with late-onset hypogonadism be discontinued?

Journal of Men's Health

Volumn 5, Issue 4, 2008, Pages 366-373

  Gooren, Louis ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Ageing male; Late onset hypogonadism; Metabolic syndrome; Testosterone

Indexed keywords

SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ABDOMINAL OBESITY; ADIPOSE TISSUE; AGING; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; DYSLIPIDEMIA; HORMONE BLOOD LEVEL; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; HYPOGONADISM; INSULIN RESISTANCE; METABOLIC SYNDROME X; PRIORITY JOURNAL; TESTOSTERONE SYNTHESIS;

EID: 56949094537     PISSN: 18756867     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jomh.2008.09.005     Document Type: Article

References (72)

1. Kaufman J.M., and Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 26 6 (2005) 833-876
2. Liu P.Y., Beilin J., Meier C., Nguyen T.V., Center J.R., Leedman P.J., et al. Age-related changes in serum testosterone and sex hormone binding globulin in Australian men: longitudinal analyses of two geographically separate regional cohorts. J Clin Endocrinol Metab 92 9 (2007) 3599-3603
3. Gray A., Feldman H.A., McKinlay J.B., and Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 73 5 (1991) 1016-1025
4. Feldman H.A., Longcope C., Derby C.A., Johannes C.B., Araujo A.B., Coviello A.D., et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 87 2 (2002) 589-598
5. Mohr B.A., Guay A.T., O'Donnell A.B., and McKinlay J.B. Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) 62 1 (2005) 64-73
6. Stellato R.K., Feldman H.A., Hamdy O., Horton E.S., and McKinlay J.B. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 23 4 (2000) 490-494
7. Muller M., den Tonkelaar I., Thijssen J.H., Grobbee D.E., and van der Schouw Y.T. Endogenous sex hormones in men aged 40-80 years. Eur J Endocrinol 149 6 (2003) 583-589
8. Mohr B.A., Bhasin S., Link C.L., O'Donnell A.B., and McKinlay J.B. The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study. Eur J Endocrinol 155 3 (2006) 443-452
9. Rodriguez A., Muller D.C., Metter E.J., Maggio M., Harman S.M., Blackman M.R., et al. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 92 9 (2007) 3568-3572
10. Kaplan S.A., Meehan A.G., and Shah A. The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men?. J Urol 176 4 Pt 1 (2006) 1524-1527 discussion 7-8
11. Allan C.A., Strauss B.J., Burger H.G., Forbes E.A., and McLachlan R.I. The association between obesity and the diagnosis of androgen deficiency in symptomatic ageing men. Med J Aust 185 8 (2006) 424-427
12. Svartberg J., Midtby M., Bonaa K.H., Sundsfjord J., Joakimsen R.M., and Jorde R. The associations of age, lifestyle factors and chronic disease with testosterone in men: the Tromso Study. Eur J Endocrinol 149 2 (2003) 145-152
13. Travison T.G., Shabsigh R., Araujo A.B., Kupelian V., O'Donnell A.B., and McKinlay J.B. The natural progression and remission of erectile dysfunction: results from the Massachusetts Male Aging Study. J Urol 177 1 (2007) 241-246 discussion 6
14. Isidori A.M., and Lenzi A. Risk factors for androgen decline in older males: lifestyle, chronic diseases and drugs. J Endocrinol Invest 28 3 Suppl (2005) 14-22
15. Derby C.A., Zilber S., Brambilla D., Morales K.H., and McKinlay J.B. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) 65 1 (2006) 125-131
16. Blouin K., Despres J.P., Couillard C., Tremblay A., Prud'homme D., Bouchard C., et al. Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metabolism 54 8 (2005) 1034-1040
17. Isidori A.M., Caprio M., Strollo F., Moretti C., Frajese G., Isidori A., et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 84 10 (1999) 3673-3680
18. Caprio M., Isidori A.M., Carta A.R., Moretti C., Dufau M.L., and Fabbri A. Expression of functional leptin receptors in rodent Leydig cells. Endocrinology 140 11 (1999) 4939-4947
19. Soderberg S., Olsson T., Eliasson M., Johnson O., Brismar K., Carlstrom K., et al. A strong association between biologically active testosterone and leptin in non-obese men and women is lost with increasing (central) adiposity. Int J Obes Relat Metab Disord 25 1 (2001) 98-105
20. Van Den Saffele J.K., Goemaere S., De Bacquer D., and Kaufman J.M. Serum leptin levels in healthy ageing men: are decreased serum testosterone and increased adiposity in elderly men the consequence of leptin deficiency?. Clin Endocrinol (Oxf) 51 1 (1999) 81-88
21. Pitteloud N., Hardin M., Dwyer A.A., Valassi E., Yialamas M., Elahi D., et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 90 5 (2005) 2636-2641
22. Lima N., Cavaliere H., Knobel M., Halpern A., and Medeiros-Neto G. Decreased androgen levels in massively obese men may be associated with impaired function of the gonadostat. Int J Obes Relat Metab Disord 24 11 (2000) 1433-1437
23. Vermeulen A., Kaufman J.M., Deslypere J.P., and Thomas G. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab 76 5 (1993) 1140-1146
24. Pritchard J., Despres J.P., Gagnon J., Tchernof A., Nadeau A., Tremblay A., et al. Plasma adrenal, gonadal, and conjugated steroids before and after long-term overfeeding in identical twins. J Clin Endocrinol Metab 83 9 (1998) 3277-3284
25. Vermeulen A., Kaufman J.M., and Giagulli V.A. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab 81 5 (1996) 1821-1826
26. Tchernof A., Labrie F., Belanger A., Prud'homme D., Bouchard C., Tremblay A., et al. Androstane-3alpha,17beta-diol glucuronide as a steroid correlate of visceral obesity in men. J Clin Endocrinol Metab 82 5 (1997) 1528-1534
27. Pritchard J., Despres J.P., Gagnon J., Tchernof A., Nadeau A., Tremblay A., et al. Plasma adrenal, gonadal, and conjugated steroids following long-term exercise-induced negative energy balance in identical twins. Metabolism 48 9 (1999) 1120-1127
28. Kaukua J., Pekkarinen T., Sane T., and Mustajoki P. Sex hormones and sexual function in obese men losing weight. Obes Res 11 6 (2003) 689-694
29. Niskanen L., Laaksonen D.E., Punnonen K., Mustajoki P., Kaukua J., and Rissanen A. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab 6 3 (2004) 208-215
30. Strain G., Zumoff B., Rosner W., and Pi-Sunyer X. The relationship between serum levels of insulin and sex hormone-binding globulin in men: the effect of weight loss. J Clin Endocrinol Metab 79 4 (1994) 1173-1176
31. Laaksonen D.E., Niskanen L., Punnonen K., Nyyssonen K., Tuomainen T.P., Valkonen V.P., et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27 5 (2004) 1036-1041
32. Kupelian V., Page S.T., Araujo A.B., Travison T.G., Bremner W.J., and McKinlay J.B. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91 3 (2006) 843-850
33. Smith R.M.L.H., and Nathan D.M. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91 (2006) 1305-1308
34. Basaria S., Muller D.C., Carducci M.A., Egan J., and Dobs A.S. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106 3 (2006) 581-588
35. Haidar A., Yassin A., Saad F., and Shabsigh R. Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. Aging Male 10 4 (2007) 189-196
36. Yialamas M.A., Dwyer A.A., Hanley E., Lee H., Pitteloud N., and Hayes F.J. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 92 11 (2007) 4254-4259
37. Ryan C.W., Huo D., Bylow K., Demers L.M., Stadler W.M., Henderson T.O., et al. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int 100 1 (2007) 70-75
38. Allan C.A., Strauss B.J., Burger H.G., Forbes E.A., and McLachlan R.I. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 93 1 (2008) 139-146
39. Munzer T., Harman S.M., Hees P., Shapiro E., Christmas C., Bellantoni M.F., et al. Effects of GH and/or sex steroid administration on abdominal subcutaneous and visceral fat in healthy aged women and men. J Clin Endocrinol Metab 86 8 (2001) 3604-3610
40. Schroeder E.T., Zheng L., Ong M.D., Martinez C., Flores C., Stewart Y., et al. Effects of androgen therapy on adipose tissue and metabolism in older men. J Clin Endocrinol Metab 89 10 (2004) 4863-4872
41. Saad F., Gooren L., Haider A., and Yassin A. An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch Androl 53 6 (2007) 353-357
42. Saad F., Gooren L.J., Haider A., and Yassin A. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl 29 1 (2008) 102-105
43. Page S.T., Amory J.K., Bowman F.D., Anawalt B.D., Matsumoto A.M., Bremner W.J., et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 90 3 (2005) 1502-1510
44. Marin P., and Arver S. Androgens and abdominal obesity. Baillière's Clin Endocrinol Metab 12 3 (1998) 441-451
45. Esmaillzadeh A., Mirmiran P., and Azizi F. Metabolic abnormalities identified by anthropometric measures in elderly men. Am J Clin Nutr 83 1 (2006) 173 Author reply: 4
46. Svartberg J., Agledahl I., Figenschau Y., Sildnes T., Waterloo K., and Jorde R. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 20 4 (2008) 378-387
47. Marin P., Oden B., and Bjorntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 80 1 (1995) 239-243
48. Anderson F.H., Francis R.M., and Faulkner K. Androgen supplementation in eugonadal men with osteoporosis - effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone 18 2 (1996) 171-177
49. Zitzmann M., and Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 92 10 (2007) 3844-3853
50. Saad F., Gooren L., Haider A., and Yassin A. Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome. Andrologia 40 (2008) 44-48
51. Liu P.Y., Wishart S.M., Celermajer D.S., Jimenez M., Pierro I.D., Conway A.J., et al. Do reproductive hormones modify insulin sensitivity and metabolism in older men? A randomized, placebo-controlled clinical trial of recombinant human chorionic gonadotropin. Eur J Endocrinol 148 1 (2003) 55-66
52. Malkin C.J., Pugh P.J., Jones R.D., Kapoor D., Channer K.S., and Jones T.H. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 89 7 (2004) 3313-3318
53. Norata G.D., Tibolla G., Seccomandi P.M., Poletti A., and Catapano A.L. Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharide-induced inflammatory response in human endothelial cells. J Clin Endocrinol Metab 91 2 (2006) 546-554
54. Isidori A.M., Giannetta E., Greco E.A., Gianfrilli D., Bonifacio V., Isidori A., et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 63 3 (2005) 280-293
55. Kapoor D., Goodwin E., Channer K.S., and Jones T.H. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 154 6 (2006) 899-906
56. Boyanov M.A., Boneva Z., and Christov V.G. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 6 1 (2003) 1-7
57. Singh A.B., Hsia S., Alaupovic P., Sinha-Hikim I., Woodhouse L., Buchanan T.A., et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 87 1 (2002) 136-143
58. Singh R., Artaza J.N., Taylor W.E., Braga M., Yuan X., Gonzalez-Cadavid N.F., et al. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology 147 1 (2006) 141-154
59. Nilsson P.M. Cardiovascular risk in the metabolic syndrome: fact or fiction?. Curr Cardiol Rep 9 6 (2007) 479-485
60. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19):2486-97.
61. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 21 (2002) 2709-2716
62. Ford E.S. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 28 11 (2005) 2745-2749
63. Valsamakis G., McTernan P.G., Chetty R., Al Daghri N., Field A., Hanif W., et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 53 4 (2004) 430-434
64. Ulijaszek S.J., and Kerr D.A. Anthropometric measurement error and the assessment of nutritional status. Br J Nutr 82 3 (1999) 165-177
65. Esposito K., Marfella R., Ciotola M., Di Palo C., Giugliano F., Giugliano G., et al. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 292 12 (2004) 1440-1446
66. Esposito K., Giugliano F., Di Palo C., Giugliano G., Marfella R., D'Andrea F., et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 291 24 (2004) 2978-2984
67. Almeida O.P., Yeap B.B., Hankey G.J., Jamrozik K., and Flicker L. Low free testosterone concentration as a potentially treatable cause of depressive symptoms in older men. Arch Gen Psychiatry 65 3 (2008) 283-289
68. Brambilla D.J., O'Donnell A.B., Matsumoto A.M., and McKinlay J.B. Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clin Endocrinol (Oxf) 67 6 (2007) 853-862
69. Travison T.G., Shackelton R., Araujo A.B., Hall S.A., Williams R.E., Clark R.V., et al. The natural history of symptomatic androgen deficiency in men: onset, progression, and spontaneous remission. J Am Geriatr Soc 56 5 (2008) 831-839
70. Tsujimura A., Takada S., Matsuoka Y., Hirai T., Takao T., Miyagawa Y., et al. Is discontinuation of hormone replacement therapy possible for patients with late-onset hypogonadism?. Int J Urol 15 7 (2008) 625-629
71. Balkau B., and Charles M.A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16 (1999) 442-443
72. Alberti K.G., Zimmet P., and Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 388 (2005) 1059-1062